From: chemistry-request at ccl.net <br />
To: chemistry-request at ccl.net<br />
Date: Sat Oct 22 17:34:14 2005<br />
Subject: 05.12.06 <span class="fancysmall">Protein Engineering, San Diego, CA</span><br />

<pre>
Protein Engineering
Defining the Next Generation of Biotherapeutics
December 6-8, 2005 - San Diego Convention Center - San Diego, CA

<a href="http://www.ibclifesciences.com/" target="_blank">http://www.ibclifesciences.com/</a>

IBC's Protein Engineering conference focuses on new protein pharmaceutical
 platforms and scientific strategies that need to be designed for 
efficient activity optimization against any specific target, and also for 
manufacturing, formulation and delivery. Presentations demonstrate how 
half-life, formulation, shelf-life, safety and non-immunogenicity 
requirements must be built into the product platform upfront so that 
every new product lead will have these properties, minimizing the need 
for additional testing in humans.

Highlights include how:

    * Avidia uses avimers to create inhibitors to block IL-6
    * Compound Therapeutics developed AdNectin as an agonist to VEGFR-2
    * Molecular Partners AG developed DARPins for diagnostic and 
      therapeutic applications
    * Dyax engineered Kunitz domain-based drug candidates that are in 
      clinical and preclinical testing
    * Genencor constructed fusion proteins between fragments of tumor 
      specific antibodies and -lactamase

2005 Scientific Advisory and Organizing Board

James W. Larrick, M.D., Ph.D., Managing Director, Panorama Research 
Institute

Andreas Plckthun, Ph.D., Professor of Biochemistry, Department of 
Biochemistry, University of Zrich, Switzerland

Robert Balint, Ph.D., Founder and CEO, CytoDesign, Inc

Bassil Dahiyat, Ph.D., President and Chief Executive Office, Xencor

Willem 'Pim' Stemmer, PhD, Founder, Avidia, Inc., and Founder and VP R&D, 
Microproteins, Inc.

Learn from World-Renowned Experts from these Organizations

    * Avidia Inc.
    * Biolex
    * Biorexis Pharmaceutical Corporation
    * Biosite Discovery
    * BioTech Studio LLC
    * Borean Pharma A/S, Denmark
    * Caltech
    * CEA, France
    * CSIRO Molecular and Health Technologies, Australia
    * Compound Therapeutics
    * CytoDesign, Inc
    * DiscoveRx Corp.
    * Dyax Corp.
    * EvoGenix, Australia
    * Genencor Intl., Inc.
    * Glycofi
    * Integrigen
    * Johns Hopkins University
    * Molecular Partners, Switzerland
    * Nektar
    * Panorama Research Institute
    * Syntonix Pharmaceuticals
    * The Carnegie Institution of Washington
    * The Scripps Research Institute
    * Trinity BioSystems, Inc.
    * University of California, San Francisco
    * University of Maryland Biotechnology Institute Center for Advanced 
      Research in Biotechnology
    * University of Zrich, Switzerland
    * Xencor</pre>
</PRE>
<B>NOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!</B><br />
All @ signs were changed to ]|[ to fight spam. Before you send e-mail, you
need to change ]|[ to @<br />
For example: change joe]|[big123comp.com to joe@big123comp.com<br />
<em>Please let colleagues know about conference listingts at
Computational Chemistry List Conference Page at</em>
<a href="http://www.ccl.net/chemistry/a/conferences/"
class="link">http://www.ccl.net/chemistry/a/conferences/</a>.